CA2652442A1 — Antitumor agent for thyroid cancer
Assigned to Eisai R&D Management Co Ltd · Expires 2007-11-29 · 18y expired
What this patent protects
It is intended to provide a pharmaceutical composition exhibiting an effe ct more effectively on at least one disease selected from the group consisti ng of multiple endocrine neoplasia type IIA, multiple endocrine neoplasia ty pe IIB, familial medullary thyroid carcinoma, thyroi…
USPTO Abstract
It is intended to provide a pharmaceutical composition exhibiting an effe ct more effectively on at least one disease selected from the group consisti ng of multiple endocrine neoplasia type IIA, multiple endocrine neoplasia ty pe IIB, familial medullary thyroid carcinoma, thyroid cancer, papillary thyr oid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung's disease, pheochromocytoma, parathyroid hyperplasia and gastrointestinal mucosal neur oma; and a therapeutic method for the same. 4-(3-chloro-4-(cyclopropylaminoc arbonyl)aminophenoxy)-7-methoxy-6-qunolinecarboxamide and an analog thereof can exhibit an effect more effectively on at least one disease selected from the group consisting of multiple endocrine neoplasia type IIA, multiple end ocrine neoplasia type IIB, familial medullary thyroid carcinoma, thyroid can cer, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirs chsprung's disease, pheochromocytoma, parathyroid hyperplasia and gastrointe stinal mucosal neuroma.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.